Unilateral temporary diaphragmatic paralysis secondary to bronchial artery embolization in a girl with cystic fibrosis and massive hemoptysis: a case report

Abstract Background Although not standard of care, Cystic Fibrosis patients with recurrent hemoptysis occasionally have coil embolization of bronchial arteries. In the event of recanalization of these arteries in this specific subset of patients, the presence of indwelling coils makes the prospect of conventional particle embolization more difficult, preventing both adequate catheterization of the coiled segment and reflux of the particles. Case presentation In this report, we describe a case of bronchial artery embolization of a complex Cystic Fibrosis patient with massive hemoptysis from recanalized coiled bronchial arteries utilizing a Scepter Balloon Catheter® (Microvention Terumo, USA) in administration of the liquid embolic agent Onyx® (Medtronic, USA). Conclusions The Scepter occlusion balloon catheter allowed for careful placement of the tip within the interstices of the pre-existing coils, allowing for Onyx injection directly into the coil mass without reflux, reconfirming the benefits of Onyx embolization in bronchial artery embolization and providing evidence that the Scepter occlusion balloon catheter should be added to the armamentarium of devices used in complex bronchial artery embolization for Cystic Fibrosis patients with massive hemoptysis.

Download Full-text

Bronchial Artery Arising from the Left Vertebral Artery: Case Report and Review of the Literature

Journal of Clinical Imaging Science ◽

10.4103/2156-7514.91135 ◽

2011 ◽

Vol 1 ◽

pp. 62 ◽

Cited By ~ 6

Author(s):

Timothy J. Amrhein ◽

Charles Kim ◽

Tony P. Smith ◽

L. Washington

Keyword(s):

Case Report ◽

Vertebral Artery ◽

Bronchial Artery ◽

Left Vertebral Artery ◽

Common Trunk ◽

Massive Hemoptysis ◽

Bronchial Artery Embolization ◽

Review Of The Literature ◽

Artery Embolization ◽

Bronchial Arteries

Knowledge of bronchial artery anatomy, including the possible locations of anomalous origin, is essential for complete catheter directed embolization for massive hemoptysis. Undetected anomalous bronchial arteries can be a source of failed bronchial artery embolization. We report a case of a common trunk bronchial artery arising from the left vertebral artery and review standard and variant bronchial artery anatomy.

Download Full-text

Massive hemoptysis two months after an otherwise mild SARS-CoV-2 disease (COVID-19) treated with bronchial artery embolization - A case report

Radiology Case Reports ◽

10.1016/j.radcr.2021.12.048 ◽

2022 ◽

Vol 17 (3) ◽

pp. 918-921

Author(s):

Gernot Rott ◽

Frieder Boecker ◽

Clemens Maurer ◽

Timur Sellmann

Keyword(s):

Case Report ◽

Bronchial Artery ◽

Massive Hemoptysis ◽

Bronchial Artery Embolization ◽

Artery Embolization

Download Full-text

Clinical outcomes of cystic fibrosis patients with hemoptysis treated with bronchial artery embolization

Jornal Brasileiro de Pneumologia ◽

10.36416/1806-3756/e20200557 ◽

2021 ◽

pp. e20200557

Author(s):

Marília Amaral Peixoto da Silveira1,2 ◽

Patrícia Amaral Peixoto da Silveira3 ◽

Flávia Gabe Beltrami1,2 ◽

Leandro Armani Scaffaro4 ◽

Paulo de Tarso Roth Dalcin1,2

Keyword(s):

Cystic Fibrosis ◽

Chronic Infection ◽

Retrospective Cohort ◽

Bronchial Artery ◽

Massive Hemoptysis ◽

Recurrent Bleeding ◽

Bronchial Artery Embolization ◽

Artery Embolization ◽

Period 2 ◽

Number Of Patients

Objective: Massive hemoptysis is one of the most serious complications in patients with cystic fibrosis (CF). This study aimed to evaluate the hemoptysis-free period following bronchial and non-bronchial artery embolization (BAE/non-BAE) in CF patients and to investigate predictors of recurrent bleeding and mortality by any cause. Methods: This was a retrospective cohort study of CF patients = 16 years of age undergoing BAE/non-BAE for hemoptysis between 2000 and 2017. Results: We analyzed 39 hemoptysis episodes treated with BAE/non-BAE in 17 CF patients. Hemoptysis recurrence rate was 56.4%. Of the sample as a whole, 3 (17.6%) were hemoptysis-free during the study period, 2 (11.8%) underwent lung transplantation, and 3 (17.6%) died. The median hemoptysis-free period was 17 months. The median hemoptysis-free period was longer in patients with chronic infection with Pseudomonas aeruginosa (31 months; 95% CI: 0.00-68.5) than in those without that type of infection (4 months; 95% CI: 1.8-6.2; p = 0.017). However, this association was considered weak, and its clinical significance was uncertain due to the small number of patients without that infection. Conclusions: BAE appears to be effective in the treatment of hemoptysis in patients with CF.

Download Full-text